Brokers Offer Predictions for Kura Oncology FY2029 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Kura Oncology in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of $12.19 per share for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

KURA has been the subject of a number of other reports. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Bank of America decreased their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Finally, Scotiabank dropped their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Stock Performance

Shares of KURA stock opened at $7.32 on Thursday. The company has a market capitalization of $569.23 million, a price-to-earnings ratio of -3.10 and a beta of 0.81. Kura Oncology has a 1-year low of $7.18 and a 1-year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $11.75 and its 200-day simple moving average is $16.95.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of KURA. nVerses Capital LLC bought a new position in Kura Oncology during the third quarter valued at about $25,000. Point72 DIFC Ltd acquired a new stake in Kura Oncology in the 3rd quarter worth approximately $146,000. Quarry LP bought a new stake in Kura Oncology during the second quarter worth approximately $196,000. Erste Asset Management GmbH acquired a new position in Kura Oncology during the third quarter valued at approximately $215,000. Finally, Bellevue Group AG raised its position in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.